Mankind Pharma Ltd.
MANKIND · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,415.08.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%12.5%
- ✓Low debt (D/E < 0.5)0.38x
- ✓Positive free cash flow
- ✓Revenue growth > 10%12%
- ✓Earnings growing32%
- ✓Net margin ≥ 10%13.4%
- ✕Current ratio > 1.51.07
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 6.24
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 6.24.
Opportunities
- •Earnings growing (32% YoY).
Threats
- •Trades ~26% above our estimated fair value.
About Mankind Pharma Ltd.
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pre
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.